StockData
Pure Bioscience, Inc. logo

Pure Bioscience, Inc. (PURE) stock

PUREOTCMiscellaneous Chemical ProductsFiscal year ends July 31
Financials through Q4 FY2026, quarter ended Jul 31, 2026Last filing: 10-K on Oct 29, 2026Score 1/30
$0.07−0.01 (-12.10%)

Close on Oct 19, 2026Market cap $8.67MP/E –Yield –

Pure Bioscience gross margin

Gross margin is gross profit as a percentage of revenue.

Pure Bioscience's gross margin for the twelve months ending Jul 31, 2026 was 57.3%. For fiscal 2026 it was 57.3%, against 59.3% the year before. The highest annual figure on record is 71.8% in fiscal 2011.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2026Jul 31, 202657.3%−2.0
FY2025Jul 31, 202559.3%+0.4
FY2024Jul 31, 202458.9%+7.0
FY2023Jul 31, 202351.9%−3.3
FY2022Jul 31, 202255.2%−1.0
FY2021Jul 31, 202156.1%−2.0
FY2020Jul 31, 202058.1%−3.7
FY2019Jul 31, 201961.9%+4.9
FY2018Jul 31, 201857.0%−1.5
FY2017Jul 31, 201758.5%−7.3
FY2016Jul 31, 201665.8%+4.9
FY2015Jul 31, 201560.9%+23.5
FY2014Jul 31, 201437.5%+6.4
FY2013Jul 31, 201331.1%−36.4
FY2012Jul 31, 201267.5%−4.3
FY2011Jul 31, 201171.8%–

Quarterly gross margin

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange (pts)
Q4 FY2026CQ2 2026Jul 31, 202656.0%−5.3
Q3 FY2026CQ1 2026Apr 30, 202653.2%−4.7
Q2 FY2026CQ4 2025Jan 31, 202653.7%−4.3
Q1 FY2026CQ3 2025Oct 31, 202563.6%+5.1
Q4 FY2025CQ2 2025Jul 31, 202561.3%+3.1
Q3 FY2025CQ1 2025Apr 30, 202557.9%−0.8
Q2 FY2025CQ4 2024Jan 31, 202558.1%+3.6
Q1 FY2025CQ3 2024Oct 31, 202458.6%−3.0
Q4 FY2024CQ2 2024Jul 31, 202458.3%+4.9
Q3 FY2024CQ1 2024Apr 30, 202458.6%+10.4
Q2 FY2024CQ4 2023Jan 31, 202454.5%+4.7
Q1 FY2024CQ3 2023Oct 31, 202361.6%+6.5
Q4 FY2023CQ2 2023Jul 31, 202353.3%+25.6
Q3 FY2023CQ1 2023Apr 30, 202348.3%−17.1
Q2 FY2023CQ4 2022Jan 31, 202349.7%−6.6
Q1 FY2023CQ3 2022Oct 31, 202255.0%−11.2
Q4 FY2022CQ2 2022Jul 31, 202227.7%−2.3
Q3 FY2022CQ1 2022Apr 30, 202265.4%+8.7
Q2 FY2022CQ4 2021Jan 31, 202256.4%−7.3
Q1 FY2022CQ3 2021Oct 31, 202166.2%−0.8
Q4 FY2021CQ2 2021Jul 31, 202130.0%−28.8
Q3 FY2021CQ1 2021Apr 30, 202156.7%+0.4
Q2 FY2021CQ4 2020Jan 31, 202163.7%+4.4
Q1 FY2021CQ3 2020Oct 31, 202067.0%+6.2
Q4 FY2020CQ2 2020Jul 31, 202058.8%−0.7
Q3 FY2020CQ1 2020Apr 30, 202056.2%−6.3
Q2 FY2020CQ4 2019Jan 31, 202059.3%−0.1
Q1 FY2020CQ3 2019Oct 31, 201960.8%−4.8
Q4 FY2019CQ2 2019Jul 31, 201959.5%+16.5
Q3 FY2019CQ1 2019Apr 30, 201962.5%+5.1
Q2 FY2019CQ4 2018Jan 31, 201959.4%−1.4
Q1 FY2019CQ3 2018Oct 31, 201865.6%−2.9
Q4 FY2018CQ2 2018Jul 31, 201843.0%−12.5
Q3 FY2018CQ1 2018Apr 30, 201857.4%−3.5
Q2 FY2018CQ4 2017Jan 31, 201860.8%−9.2
Q1 FY2018CQ3 2017Oct 31, 201768.5%+18.4
Q4 FY2017CQ2 2017Jul 31, 201755.5%–
Q3 FY2017CQ1 2017Apr 30, 201760.9%–
Q2 FY2017CQ4 2016Jan 31, 201770.0%–
Q1 FY2017CQ3 2016Oct 31, 201650.1%–

More Pure Bioscience figures

See a number that looks wrong?